{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"31.9","value":"15.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"The ORR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). The overall response category was derived based on response assessment performed on or before the start of subsequent anti-cancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 20, 30, 45, 60, 80, 100, 125 and 150 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"ADCT-301 Monotherapy"},{"description":"Participants received 20, 30, 45, 60, 80 and 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG001","title":"ADCT-301 Combination Therapy"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set: The Efficacy analysis set consisted of all participants who received at least 1 dose of study drug, had valid Baseline disease assessment(s), and at least one valid post-Baseline disease assessment. Participants who did not have a post-Baseline assessment due to early clinical progression or death (after receiving study drug) were also included. The monotherapy arms and combination arms were pooled as pre-specified in protocol section 3.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Response Rate (ORR) According to the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.","type":"SECONDARY","unitOfMeasure":"percentage of participants"}